Literature DB >> 26846855

Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling.

Pardeep Heir1, Tharan Srikumar2, George Bikopoulos1, Severa Bunda1, Betty P Poon3, Jeffrey E Lee1, Brian Raught2, Michael Ohh4.   

Abstract

von Hippel-Lindau (VHL) disease is a rare familial cancer predisposition syndrome caused by a loss or mutation in a single gene,VHL, but it exhibits a wide phenotypic variability that can be categorized into distinct subtypes. The phenotypic variability has been largely argued to be attributable to the extent of deregulation of the α subunit of hypoxia-inducible factor α, a well established target of VHL E3 ubiquitin ligase, ECV (Elongins/Cul2/VHL). Here, we show that erythropoietin receptor (EPOR) is hydroxylated on proline 419 and 426 via prolyl hydroxylase 3. EPOR hydroxylation is required for binding to the β domain of VHL and polyubiquitylation via ECV, leading to increased EPOR turnover. In addition, several type-specific VHL disease-causing mutants, including those that have retained proper binding and regulation of hypoxia-inducible factor α, showed a severe defect in binding prolyl hydroxylated EPOR peptides. These results identify EPOR as the secondbona fidehydroxylation-dependent substrate of VHL that potentially influences oxygen homeostasis and contributes to the complex genotype-phenotype correlation in VHL disease.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  E3 ubiquitin ligase; EPOR; PHD3; VHL; cell signaling; hypoxia; prolyl hydroxylation; protein degradation; ubiquitylation (ubiquitination)

Mesh:

Substances:

Year:  2016        PMID: 26846855      PMCID: PMC4817168          DOI: 10.1074/jbc.M115.694562

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.

Authors:  William Y Kim; Michal Safran; Marshall R M Buckley; Benjamin L Ebert; Jonathan Glickman; Marcus Bosenberg; Meredith Regan; William G Kaelin
Journal:  EMBO J       Date:  2006-09-14       Impact factor: 11.598

2.  Increased cell surface expression of C-terminal truncated erythropoietin receptors in polycythemia.

Authors:  T Motohashi; Y Nakamura; M Osawa; T Hiroyama; A Iwama; A Shibuya; H Nakauchi
Journal:  Eur J Haematol       Date:  2001-08       Impact factor: 2.997

3.  A conserved family of prolyl-4-hydroxylases that modify HIF.

Authors:  R K Bruick; S L McKnight
Journal:  Science       Date:  2001-10-11       Impact factor: 47.728

4.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Authors:  A C Epstein; J M Gleadle; L A McNeill; K S Hewitson; J O'Rourke; D R Mole; M Mukherji; E Metzen; M I Wilson; A Dhanda; Y M Tian; N Masson; D L Hamilton; P Jaakkola; R Barstead; J Hodgkin; P H Maxwell; C W Pugh; C J Schofield; P J Ratcliffe
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

5.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

6.  The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C.

Authors:  H Okuda; K Saitoh; S Hirai; K Iwai; Y Takaki; M Baba; N Minato; S Ohno; T Shuin
Journal:  J Biol Chem       Date:  2001-09-26       Impact factor: 5.157

7.  CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2.

Authors:  A Sasaki; H Yasukawa; T Shouda; T Kitamura; I Dikic; A Yoshimura
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

8.  von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.

Authors:  M A Hoffman; M Ohh; H Yang; J M Klco; M Ivan; W G Kaelin
Journal:  Hum Mol Genet       Date:  2001-05-01       Impact factor: 6.150

9.  Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

Authors:  S C Clifford; M E Cockman; A C Smallwood; D R Mole; E R Woodward; P H Maxwell; P J Ratcliffe; E R Maher
Journal:  Hum Mol Genet       Date:  2001-05-01       Impact factor: 6.150

10.  The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor.

Authors:  L J Huang; S N Constantinescu; H F Lodish
Journal:  Mol Cell       Date:  2001-12       Impact factor: 17.970

View more
  15 in total

1.  Effect of high altitude on human placental amino acid transport.

Authors:  Owen R Vaughan; Fredrick Thompson; Ramón A Lorca; Colleen G Julian; Theresa L Powell; Lorna G Moore; Thomas Jansson
Journal:  J Appl Physiol (1985)       Date:  2019-12-05

Review 2.  Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer.

Authors:  Maxwell Shulman; Rachel Shi; Qing Zhang
Journal:  J Genet Genomics       Date:  2021-07-09       Impact factor: 5.723

Review 3.  New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.

Authors:  Giada Zurlo; Jianping Guo; Mamoru Takada; Wenyi Wei; Qing Zhang
Journal:  Biochim Biophys Acta       Date:  2016-09-20

4.  Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates.

Authors:  Matthew E Cockman; Kerstin Lippl; Ya-Min Tian; Johanna Myllyharju; Christopher J Schofield; Peter J Ratcliffe; Hamish B Pegg; William D Figg; Martine I Abboud; Raphael Heilig; Roman Fischer
Journal:  Elife       Date:  2019-09-10       Impact factor: 8.140

Review 5.  Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases.

Authors:  Chengheng Liao; Qing Zhang
Journal:  Am J Pathol       Date:  2020-04-24       Impact factor: 4.307

6.  The long form of pVHL is artifactually modified by serine protease inhibitor AEBSF.

Authors:  Daniel Tarade; Shelley He; Jonathan St-Germain; Avi Petroff; Anya Murphy; Brian Raught; Michael Ohh
Journal:  Protein Sci       Date:  2020-06-25       Impact factor: 6.725

7.  Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides.

Authors:  Laura Hulea; Simon-Pierre Gravel; Masahiro Morita; Marie Cargnello; Oro Uchenunu; Young Kyuen Im; Camille Lehuédé; Eric H Ma; Matthew Leibovitch; Shannon McLaughlan; Marie-José Blouin; Maxime Parisotto; Vasilios Papavasiliou; Cynthia Lavoie; Ola Larsson; Michael Ohh; Tiago Ferreira; Celia Greenwood; Gaëlle Bridon; Daina Avizonis; Gerardo Ferbeyre; Peter Siegel; Russell G Jones; William Muller; Josie Ursini-Siegel; Julie St-Pierre; Michael Pollak; Ivan Topisirovic
Journal:  Cell Metab       Date:  2018-09-20       Impact factor: 27.287

Review 8.  VHL and Hypoxia Signaling: Beyond HIF in Cancer.

Authors:  Jing Zhang; Qing Zhang
Journal:  Biomedicines       Date:  2018-03-19

9.  HIF-2α-pVHL complex reveals broad genotype-phenotype correlations in HIF-2α-driven disease.

Authors:  Daniel Tarade; Claire M Robinson; Jeffrey E Lee; Michael Ohh
Journal:  Nat Commun       Date:  2018-08-22       Impact factor: 14.919

10.  Evolution of metazoan oxygen-sensing involved a conserved divergence of VHL affinity for HIF1α and HIF2α.

Authors:  Daniel Tarade; Jeffrey E Lee; Michael Ohh
Journal:  Nat Commun       Date:  2019-07-23       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.